immunotherapy

Case Q&A

Cutaneous Squamous Cell Carcinoma of the Scalp: The Role of Surgery, Nonsurgical Intervention, and Immunotherapy

04/26/2024

Madison Tyle

Bilal Koussayer

Nikhita Nookala

Nicole K. Le

Kristen Whalen

Kristina T. Gemayel

Michael Harrington

This Case Q&A presents an 84-year-old male with advanced squamous cell carcinoma of the scalp.

This Case Q&A presents an...

04/26/2024

ePlasty

Case Report

Case Report and Literature Review of Giant Cutaneous Malignant Melanoma: What’s Keeping Patients Away?

09/23/2022

Jamie A Mawhinney, BA, BMBCh, MRCS (Eng)¹; Adrien Yvon, MBChB, MRes (Dist), MRCS (Eng)¹; Shahid Masood, MBBS, FFCPS (Plast), FRCS (Plast)¹

Jamie A Mawhinney, BA, BMBCh, MRCS (E...

This case report presents one of the largest cases of giant cutaneous malignant melanoma to date and the first in the literature to show excellent response to adjuvant immunotherapy.

This case report presents one of...

09/23/2022

ePlasty

News

Optimal Real-World Immunochemotherapy Regimen for Patients With MCL

06/25/2020

A study presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) shed light on real-world outcomes in patients with mantle cell lymphoma (MCL) who were treated with rituximab plus...

A...

06/25/2020

Journal of Clinical Pathways

Research Reports

The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis

05/19/2020

Abdalla Aly, PhD

Courtney Johnson, MPH

Yunes Doleh, MPH, PharmD

Viktor Chirikov, MS, PhD

Marc Botteman, MSc

Rahul Shenolikar, MS, PhD

Arif Hussain, MD

Abstract: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer’s perspective, the lifetime costs among patients diagnosed with UC...

...

05/19/2020

Journal of Clinical Pathways

From the Field

Evolving the Delivery of CAR T-Cell Therapies to the Outpatient Setting

10/15/2018

Sandy Smith, RN, MSN, AOCN

James Essell, MD

Abstract: The availability of adoptive cell therapies allows clinicians to genetically reprogram patients’ own immune cells to find and attack cancer cells throughout the body. Chimeric antigen receptor (CAR)...

...

10/15/2018

Journal of Clinical Pathways

Research in Review

Novel Prostate Cancer Biomarkers May Improve Targeted Therapy

08/15/2017

JCP Editors

Recent research has uncovered a new cause of treatment resistance in prostate cancer, which may improve targeted therapy efforts. Mutations within the SPOP gene are the most frequently documented genetic changes in...

Recent...

08/15/2017

Journal of Clinical Pathways

Research in Review

Monotherapy Improves Outcomes in Metastatic Breast Cancer With BRCA Mutation

08/14/2017

JCP Editors

An immuno-agent improves progression-free survival (PFS) and lowers the risk of death for patients with human epidermal growth factor 2 (HER2)-negative metastatic breast cancer and a germline BRCA mutation, according...

An...

08/14/2017

Journal of Clinical Pathways

Research in Review

Comparative Effectiveness Study Identifies Optimal Therapy for MCL

08/02/2017

JCP Editors

A recent study showed improved long-term survival outcomes and quality of life (QoL) for patients with mantle cell lymphoma (MCL) receiving tyrosine kinase inhibitor (TKI) therapy compared with those receiving...

A...

08/02/2017

Journal of Clinical Pathways

Research in Review

Optimal Therapy for Type of B-Cell Malignancy

08/02/2017

JCP Editors

A...

08/02/2017

Journal of Clinical Pathways

Research in Review

QoL Improved for Patients With Head and Neck Cancer After Immunotherapy

06/27/2017

JCP Editors

An immunotherapy agent drastically improved patient-reported quality of life (QoL) in short and long-term analyses compared with conventional chemotherapy for patients with head and neck cancer, according to research...

An...

06/27/2017

Journal of Clinical Pathways